GIMBE - AME-AACE 2002


	Associazione Medici Endocrinologi	2nd AME Italian Meeting Associazione Medici Endocrinologi Joint Meeting with AACE American Association of Clinical Endocrinologists Reggio Emilia, Italy - November 8-10, 2002
	American Association of Clinical Endocrinologists

Clinical symposia Chairman: Antonino Cartabellotta (Palermo, Italy)

Methodological Issues

Hyperlipidemia Om Ganda (Boston, USA), Angela Rivellese (Naples, Italy)
Slides Final remarks Om Ganda Evidence appraised Practice guidelines National Heart, Blood and Lung Institute Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) ATP III Full Report ATP III Executive Summary JAMA 2001;285:2486-97 American Diabetes Association. Clinical Practice Recommendations 2002 Management of Dyslipidemia in Adults With Diabetes Programma Nazionale Linee Guida Documento di indirizzo: Colesterolo L'uso delle carte di rischio per identificare gli individui a rischio coronarico aumentato Filosofia, vantaggi, limiti e applicabilità SIGN - Scottish Intercollegiate Guidelines Network Management of diabetes Management of diabetic cardiovascular disease Lipids and the primary prevention of coronary heart disease. 1999 Primary prevention in people with diabetes mellitus Technology assessment reports None Systematic reviews None Narrative reviews, editorials Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. American College of Cardiology/American Heart Association/National Heart, Lung and Blood Institute. Circulation 2002;106:1024-8 Winocour PH. Effective diabetes care: a need for realistic targets. BMJ 2002;324:1577-80. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570-81 Winocour PH. Effective diabetes care: a need for realistic targets. BMJ. 2002 Jun 29;324(7353):1577-80. Gotto AM. Lipid management in diabetic patients: lessons from prevention trials. Am J Med. 2002 Jun 3;112 Suppl 8A:19S-26S [abstract] Steiner G. Lipid intervention trials in diabetes. Diabetes Care. 2000 Apr;23 Suppl 2:B49-53 Armitage J, Collins R. Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials. Heart 2000;84:357-60 Primary research RCTs Published Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22 The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001;24:1335-41. Diabetes Atherosclerosis Intervention Study Investigators.Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Interventions Study, a Randomized Study. Lancet 2001;357:905–910. Elekels RS, Diamond JR, Poulter CD, et al.Cardiovascular outcomes in type 2 diabetes: a double-blind placebo-controlled study of bezafibrate: St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998;21:641-648 Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-7 In progress Colhoun HM, Thomason MJ, Mackness MI, et al Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med 2002 Mar;19:201-11 Other studies Evans JMM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 dibatese and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 2002;324:939-42 Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234 Diabetes Trials Unit UKPDS Risk Engine. Calculates risk estimates for individuals with type 2 diabetes Adler AI, Stratten IM, Holman RR, et al. The UKPDS Risk Engine: a model for the risk of coronary heart disease in type 2 diabetes. Clinical Science 2001;101:671-679
Therapeutic options in obesity Richard Dickey (Winston-Salem, NC, USA), Francesco Giorgino (Bari, Italy)
Slides Final remarks. Richard Dickey Evidence appraised Practice guidelines National Heart, Lung, and Blood Institute, North American Association for the Study of Obesity The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. Bethesda, Md, 2000 (NGC complete summary) American Association of Clinical Endocrinologists/American College of Endocrinology. AACE/ACE position statement on the prevention, diagnosis and treatment of obesity. Revised 1998 (NGC complete summary) Prodigy (UK). Obesity Canadian Task Force on Preventive Health Care. Periodic health examination, 1999 update: 1. Detection, prevention and treatment of obesity American Society for Bariatric Surgery. Society of American Gastrointestinal Endoscopic Surgeons. Guidelines for laparoscopic and open surgical treatment of morbid obesity. Obes Surg 2000;10:378-9 Technology assessment reports UK Health Technology Assessment Programme The clinical effectiveness and cost-effectiveness of surgery for people with morbid obesity: a systematic review and economic evaluation. Health Technology Assessment 2002; Vol. 6: No. 12 The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment. Health Technology Assessment 2002; Vol. 6: No. 6 A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess 2001 Vol 5 No 18 National Institute for Clinical Excellence. Obesity (morbid) – surgery SBU. Obesity – Problems and Interventions ASERNIP - Australian Safety and Efficacy Register of New Interventional Procedures. Surgical Laparoscopic adjustable gastric banding. June 2000 Alberta Heritage Foundation for Medical Research. Laparoscopic adjustable gastric banding for clinically severe (morbid) obesity. December 2000 Wessex Institute for Health Research & Development, University of Southampton. Allgood P. Surgical interventions for morbid obesity. December 2001 Systematic reviews Cochrane Advice on low-fat diets for obesity (Cochrane Review) Improving health professionals' management and the organisation of care for overweight and obese people (Cochrane Review) Protocols Shaw K, Del Mar C, O'Rourke P, Tito F. Exercise for obesity (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 3, 2002. Oxford: Update Software Shaw K, Kenardy J, O'Rourke P, Del Mar C. Psychological interventions for obesity (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 3, 2002. Oxford: Update Software. Colquitt J, Clegg A, Sidhu M, Royle P. Surgery for morbid obesity (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 3, 2002. Oxford: Update Software Non-Cochrane Haddock CK, Poston WS, Dill PL, et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002;26:262-73 [abstract] Gentileschi P, Kini S, Catarci M, Gagner M. Evidence-based medicine: open and laparoscopic bariatric surgery. Surg Endosc 2002;16:736-44 [abstract] Anderson JW, Konz EC, Frederich RC, et ak. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 2001;74:579-84 [abstract]. Narrative reviews Polly Hitchcock NoÎl, Pugh JA. Management of overweight and obese adults. BMJ 2002;325:757–61 Yanovski S. Z., Yanovski J. A. Drug Therapy: Obesity. N Engl J Med 2002;346:591-602 Glazer G. Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med 2001;161:1814-24